Interní Med. 2002; 4(12): 15-19

Dermatologické aspekty sérologického stanovení antinukleárních protilátek

RNDr. Miloslav Hlubinka
Dermatovenerologická klinika, FN Brno

Keywords: antinuclear antibodies, autoimmunity, indirect immunofluorescence, ELISA, immunoblotting.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hlubinka M. Dermatologické aspekty sérologického stanovení antinukleárních protilátek. Interní Med. 2002;4(12):15-19.

Rozvoj moderní imunologie významným způsobem napomohl odhalení autoimunitního podtextu etiopatogeneze mnohých dermatóz. Stanovení autoprotilátek se stalo nepostradatelným pomocníkem při diferenciální diagnostice některých koľních onemocnění. V diagnostice autoimunitních dermatóz hraje klíčovou úlohu stanovení antinukleárních protilátek. Proto je zde prezentován alespoň základní přehled o této poměrně heterogenní (alespoň co se týče antigenních epitopů, proti kterým jsou zaměřeny) skupině autoprotilátek. V současné době je znám značný počet antigenních epitopů v buněčném jádru, proti kterým mohou autoprotilátky vznikat. Nepřehlédnutelná část z nich má význam i pro dermatologii.

Dermatological aspects of serologic assay of antinuclear antibodies

Advances in contemporary immunology have contributed a great deal in disclosure of an autoimmune nature in pathogenesis of many dermatosis. Determination of antibody levels represents an indispensable help in differential diagnosis of some skin diseases. The antinuclear antibodies assay is crucial in diagnosis of autoimmune dermatosis. Therefore an essential survey of this heterogennous group of antibodies (referring to the antigenic epitopes against which they are directed) is presented. According to current knowledge, a large number of the antigenic epitopes are differentiated in cell core, against which the antibodies might be originated. The vast amount of them is of a great significance in dermatology.

Download citation

References

  1. Alilat M, Sivolob A, Revet B, Prunell A. Nucleosome dynamics. Protein and DNA contributions in the chiral transition of the tetrasome, the histone (H3-H4)2 tetramer-DNA particle. J Mol Biol 1999; 291(4): 815-841. Go to original source... Go to PubMed...
  2. Bardana EJ Jr, Malinow MR, Houghton DC, McNulty WP, Wuepper KD, Parker F, Pirofsky B. Diet-induced systemic lupus erythematosus (SLE) in primates. Am J Kidney Dis 1982; 1(6): 345-352. Go to original source... Go to PubMed...
  3. Blomberg S, Ronnblom L, Wallgren AC, Nilsson B, Karlsson-Parra A. AntiSSA/Ro antibody determination by enzyme-linked immunosorbent assay as a supplement to standard immunofluorescence in antinuclear antibody screening. Scand J Immunol 2000; 51(6): 612-617. Go to original source... Go to PubMed...
  4. Bradwell AR, Stokes RP, Johnson GD. Atlas of HEp-2 patterns. ISBN 0704416220, KNP Group Ltd, Redditch, UK 1995; 118.
  5. Burch JM, Lee LA, Weston WL. Neonatal lupus erythematosus. Dermatol Nurs 2002; 14(3): 157-160. Go to PubMed...
  6. Friou GJ. Setting the scene: a historical and personal view of immunologic diseases, autoimmunity and ANA. Clin Exp Rheumatol 1994; 12(Suppl 11): 23-25. Go to PubMed...
  7. Hang LM, Nakamura RM. Current concepts and advances in clinical laboratory testing for autoimmune diseases. Crit Rev Clin Lab Sci 1997; 34(3): 275-311. Go to original source... Go to PubMed...
  8. Konarska MM, Sharp PA. Interactions between small nuclear ribonucleoprotein particles in formation of spliceosomes. Cell 1987 Jun 19; 49(6): 763-774. Go to original source... Go to PubMed...
  9. Malleson PN, Sailer M, Mackinnon MJ. Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child 1997; 4: 299-304. Go to original source... Go to PubMed...
  10. Margaux J, Hayem G, Palazzo E, Chazerain P, De Bandt M, Haim T, Kahn MF, Meyer O. Clinical usefulness of antibodies to U1snRNP proteins in mixed connective tissue disease and systemic lupus erythematosus. Rev Rhum Engl Ed 1998; 6: 378-386.
  11. Mitchell AJ, Rusin LJ, Diaz LA. Circumscribed scleroderma with immunologic evidence of systemic lupus erythematosus. Arch Dermatol 1980 Jan; 116 (1):69-73. Go to original source... Go to PubMed...
  12. Salomonsson S, Dorner T, Theander E, Bremme K, Larsson P, Wahren-Herlenius M. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 2002; 5: 1233-1241. Go to original source... Go to PubMed...
  13. Swaak T, Smeenk R. Detection of anti-dsDNA as a diagnostic tool: a prospective study in 441 non-systemic lupus erythematosus patients with anti-dsDNA antibody (anti-dsDNA). Ann Rheum Dis 1985; 4: 245-251. Go to original source... Go to PubMed...
  14. Vencovský J. Autoimunitní systémová onemocnění. Triton, Praha 1998: 20-21.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.